Clinical Trial Update: Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence [Phase 2]

View source ↗

Summary

Clinical trial update on a Phase 2 long-term biweekly study of occidiofungin to suppress recurrence of vulvovaginal candidiasis; the study is not yet recruiting…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Vulvovaginal Candidiasis

Drugs mentioned

• Occidiofungin (occidiofungin)

Snippet

Sponsor: Sano Chemicals Inc | Conditions: Candidiasis, Vulvovaginal | Phase 2 | Status: NOT_YET_RECRUITING